IDH1 and IDH2 mutations result in the production of reduced alpha-ketoglutarate (α-KG) levels and increased 2-hydroxyglutarate (2-HG), which influence histone and DNA methylation profiles in glioma [192]. Here, IDH2 is linked to central nervous system cancer.